Bussin Science Investor
Investor Focused on Risk/Reward
Biotech is drawing some of the largest long-term buying ever into the SPDR S&P Biotech ETF as it pushes toward its 2021 all-time high. Heavy buy volume, including another historic dollar-volume spike last week, matters more than short-term uncertainty, and the selling has been inefficient. If price loses $154.20 again, the bear case comes back into play. x.comÂ
Biotech is back. A quoted report says lab monkey prices in China have surged to about $26,000 each as the biotech boom overwhelms supply. x.comÂ
Biotech looks weak as rates finally appear to be weighing on the sector. The biotech ETF closed red well below its 50-day moving average, its 100-day is below its 150-day, and the chart is messy. x.comÂ
Biotech looks like a sector that wants to trend higher. Biotech M&A drove a heavy-volume weekly move to the top of a multi-month range; it just needs some help from the macro environment. x.comÂ
Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.comÂ
US healthcare and biotech stocks are coming under distribution as the attack on healthcare returns. Per Dr Alex Kenton, the No Surprises Act has knocked millions of people off insurance rolls, hurting hospitals, and a new Justice Department investigation targets Cigna, UnitedHealth and CVS over allegedly using Claritev to fix prices. x.comÂ
Biotech stocks are breaking out of a five-year range because the threat from oil and interest rates was priced in years ago. Many of the most undervalued growth stocks are now in biotech, and research discovery is getting a boost from AI, making it perhaps the sector with most to gain from AI productivity. Charts support it: daily volume spikes have tended to mark major bottoms, the weekly held its quarterly averages to form a base, and the monthly shows a healthy pullback to the one-year EMA. … Show more
Moderna, biotech stocks, AbbVie and Amgen have bullish chart setups. Their daily charts are in uptrends, with the latest strong bullish candles confirming momentum alongside steady, strong whale accumulation. x.comÂ
Summit Therapeutics' leaders bought at the lows, a strong signal ahead of the November 14 FDA decision date for ivonescimab. Co-CEO Robert Duggan bought 3.81M shares twice at $13.12, about $100M, the same week Summit pulled a $500M stock offering, choosing personal cash over dilution. Phase 3 HARMONi-6 showed ivonescimab cut the risk of death 34% versus tislelizumab combinations in first-line squamous NSCLC. A pennant breakout above $15.88 could run toward the $20s. x.com x.comÂ
uniQure and ClearPoint Neuro look very bullish on the Wall Street Journal report that President Trump is expected to remove FDA Commissioner Marty Makary. x.comÂ